GOODMAN COREY S 4

What Happened
Corey S. Goodman, reported as a 10% owner of ALX Oncology (ALXO), made a purchase of 3,184,713 shares on Feb 2, 2026 at $1.57 per share, for a total reported purchase value of $4,999,999. This filing (Form 4) reports a straight purchase (transaction code P), which is a direct buy of company stock rather than a sale or option exercise.

Key Details

• Transaction date: 2026-02-02; Filing date: 2026-02-04 (timely filing).
• Price and amount: 3,184,713 shares at $1.57 each; total = $4,999,999.
• Transaction type: P = Purchase (open market or private purchase).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes of note:
  • Several blocks of shares are held of record by venBio entities (venBio Global Strategic Fund II, venBio Global Strategic Fund, venBio SPV, LLC) and other entities (Goodman Barinaga Trust; Emaldi Corporation). Goodman is a director/trustee/manager for these entities and disclaims direct beneficial ownership except for indirect pecuniary interests (see F1–F5).
• No derivative transactions, awards, gifts, or tax-withholding reported in this filing.

Context
This is a purchase by a reported 10% owner and affiliated institutional entities (venBio-related funds and related vehicles), not an ordinary executive salary sale. Purchases by insiders or large holders can be viewed as a positive signal of conviction, but filings do not state the buyer’s motivation. The filing is straightforward and timely; there’s no indication of option exercises, sales, or 10b5-1 plans in this report.